



STATE OF OKLAHOMA }  
 IN THE DISTRICT COURT OF CLEVELAND COUNTY } S.S.  
 STATE OF OKLAHOMA }

**FILED**

**JUN 10 2019**

STATE OF OKLAHOMA, ex rel., )  
 MIKE HUNTER, )  
 ATTORNEY GENERAL OF OKLAHOMA, )  
 )  
 Plaintiff, )  
 )  
 vs. )  
 )  
 PURDUE PHARMA L.P., et al., )  
 )  
 Defendants. )

In the office of the  
 Court Clerk MARILYN WILLIAMS

Case No. CJ-2017-816  
 The Honorable Thad Balkman  
 Special Master: William Hetherington

**PURDUE PHARMA L.P., PURDUE PHARMA, INC. AND THE PURDUE FREDERICK  
 COMPANY RECORDS STIPULATION NO. 7**

Purdue Pharma, L.P., Purdue Pharma, Inc. and The Purdue Frederick Company (“Purdue”) hereby stipulate and agree that the following facts are true and correct:


1. During the course of the above-styled and numbered cause (“Action”), and in response to one or more discovery requests from Plaintiff to Purdue, Purdue produced to Plaintiff the following document generally described as follows:

<b>Exhibit No.</b>	<b>Summary Description</b>
1	6-page document--Written answers to certain 30(b)(6) Topics
2	4-page document entitled Opioid pseudoaddiction – an iatrogenic syndrome
3	16-page document entitled Use of Opioids in Chronic Non-Cancer Pain
4	82-page document entitled Pain Management: The 5 <sup>th</sup> Vital Sign and containing one or more presentation documents
5	4-page document entitled Public Relations Program
6	12-page document entitled Issues Monitoring Report, March 2001 Analysis
7	40-page document entitled Leadership Summit on Pain Management
8	10-page document entitled Purdue Actions
9	63-page document entitled OxyContin Abuse and Efforts to Address the Problem
10	4-page document entitled The Use of Opioids for the Treatment of Chronic Pain
11	Letter to AG Jody Collins Jon Sale re: Production of “Model Guidelines”

<b>Exhibit No.</b>	<b>Summary Description</b>
12	68-page document entitled Principles of Analgesic Use in the Treatment of Pain and Cancer Pain
13	1-page document entitled Oklahoma Speaker Program Data
14	1-page document containing correspondence from R. Portenoy
15	4-page document entitled Communications and External Affairs Committee August 14 <sup>th</sup> Minutes/Action Items
16	PowerPoint Presentation re: Patient Retention Program
17	The Fifth Vital Sign: New Standards for Effective Pain Management
18	April 13, 2011 letter from Medical Societies to House Subcommittee
19	CV of Sunil J. Panchal, M.D.
20	CV of Judith A. Paice, PhD, RN, FAAN
21	CV of Seddon R. Savage MD, MS
22	November 2010 Article in the Journal of Pain and Symptom Management, Long-Term Safety and Tolerability of Fentanyl Buccal Tablet for the Treatment of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Pain: An 18-Month Study
23	CV of Michael J. Brennan, MD
24	CV of Perry C. Fine, MD
25	CV of Michael J. Brennan, M.D.
26	CV of Steven D. Passik, Ph.D.
27	CV of Bill McCarber, MD
28	September 2, 1997 Oklahoma Pain Project Letter from Mary Perin to Harry Lazarus
29	Oklahoma Pain Project Grant Proposal for Leadership Program Phase II, Sept. 1997-Feb. 1998
30	Oklahoma Pain Project Grant Proposal for Flyer Printing Costs, Sept. 1997-Nov.1997
31	Massachusetts Pain Initiative 2009 Winter Bulletin
32	ACPA Chronicle August 2015
33	June 13, 2006 The Epidemic of Pain in America Report
34	Article by Perry Fine from Journal of Pain and Symptom Management, Nov. 5. 2010, Long-Term safety and Tolerability of Fentanyl Buccal Tablet for Treatment of Breakthrough Pain.
35	Steven Passik Article

2. The documents identified as Exhibit 1 through Exhibit 35 in paragraph 1 are exact duplicates of documents within the possession and control of Purdue that were produced in this Action as identified in paragraph 1.

Stipulated and agreed this 3rd day of June, 2019.

A large, bold, handwritten signature in black ink, appearing to be "John T. Cox", written over a horizontal line.

John T. Cox  
Lynn Pinker Cox & Hurst  
2100 Ross Avenue, Suite 2700  
Dallas, Texas 75201

*Attorneys for Purdue Pharma, LP,  
Purdue Pharma, Inc. and The  
Purdue Frederick Company*